CHIMERIX INC (CMRX) Stock Price, Quote, News and Overview
NASDAQ:CMRX - Nasdaq - US16934W1062 - Common Stock
CMRX Quote and Key Statistics
CHIMERIX INC
NASDAQ:CMRX (1/21/2025, 8:00:00 PM)
Premarket: 3.85 +0.01 (+0.26%)3.84
+0.29 (+8.17%)
CMRX Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.68% | ||
| ROE | -61.57% | ||
| Debt/Equity | 0 |
CMRX Performance and Technical Analysis
CMRX Ownership and Analysts
CMRX Latest News and Analysis
Chimerix to Speak Today at The White House Cancer Moonshot Forum
Chief Scientific Officer, Joshua E. Allen, Ph.D. to Highlight Cancer Moonshot’s Impact on Brain Cancer and Rare Pediatric Disease Drug Development
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility...
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?
On Monday, Chimerix (NASDAQ:CMRX) announced that, following extensive dialogue with the FDA, the company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone for recurrent H3 K27M-mutant diffuse glioma in the U.S. before year-end. A glioma is a tumor that originates in the glial cells of the brain or spinal cord and is the most common primary brain tumor. Chimerix stock is trading higher on a strong session volume of 4.31 million, compared to an ave
About CMRX
Company Profile
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 72 full-time employees. The company went IPO on 2013-04-11. The firm is focused on developing medicines that address unmet medical needs. The firm's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The firm's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with differential specificity and function. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides, also includes approximately 3,500 nucleosides.
Company Info
CHIMERIX INC
2505 Meridian Parkway, Suite 100
Durham NORTH CAROLINA 27713 US
CEO: Michael A. Sherman
Employees: 72
Company Website: https://www.chimerix.com/
Investor Relations: https://ir.chimerix.com/
Phone: 19198061074
CMRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |